Christian Hordo - Dec 15, 2023 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: EVP, Chief Business Officer
Signature: /s/ Julie Shah, Attorney-in-Fact for Christian Hordo
Stock symbol: SANA
Transactions as of: Dec 15, 2023
Transactions value $: -$300,098
Form type: 4
Date filed: 12/18/2023, 04:51 PM
Previous filing: Nov 3, 2023
Next filing: Mar 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Sale	-$300K	-75K	-7.96%	$4.00	867K	Dec 15, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021, as modified on April 11, 2023.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.10, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021, as modified on April 11, 2023.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.10, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.